Although I was responding about the HCV programs of various companies it is very true that GILD will have other new income.
I also believe I noticed some increases in HIV pricing.
GILD has long had a reputation for keeping their pricing high.
It is also for this reason I have thought that the discounts they are offering for HCV regimens may not slashed as low as some are interpreting, or that if they are cut, it is a means of achieving a larger market share or preferred status.
I am hoping that this down period is echoing the one of last year. Many companies were down till right around earnings, then there was a significant and steady recovery.
Market Data 
Markets 
AI
